Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours ยท Estimated delivery Oct 6 - Oct 11
Individuals with T2DM frequently have multiple cardiovascular risk factors, including obesity (32.9%), hypertension (32-80%), and dyslipidemia (39%) ( The association between glycemic control and cardiovascular outcomes in DM patients has been long studied ( To address these challenges, novel pharmacological therapies such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged, offering cardioprotective benefits ( The aim of this review is to enhance our understanding of the role of SGLT-2i and GLP-1 RAs in managing patients with T2DM and CVD
Yet here we are
Knudsen LB, Nielsen PF, Huusfeldt PO, et al
What About Other Diabetes Medications
Cho PG, Jang JH, Ko S, Shin DA, Chung S, Chang MC (2023) The Effect of Evogliptin Tartrate on Controlling Inflammatory Pain
US$ 23.16
US$ 25.06
US$ 21.48
US$ 21.57
US$ 20.12
US$ 29.61
